A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2017 Planned primary completion date changed from 1 Feb 2016 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 28 Sep 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.